Inhibition of Microarterial Thrombosis by Activated Protein C in a Rabbit Model

 

PDF Download Buy Article Permissions and Reprints

Summary

Protein C is the key component in a natural anticoagulant pathway. After its activation by the thrombin-thrombomodulin complex, it degrades the activated forms of coagulation cofactors VIII and V, which leads to downregulation of the coagulation process. Due to its specific anticoagulant activity, activated protein C (APC) is potentially interesting as an antithrombotic agent. The effect of bovine activated protein C on thrombus formation and haemostasis was investigated in a rabbit model of microarterial thrombosis. Segments of both central ear arteries were prepared and blood-flow interrupted with double vascular clamps.

Longitudinal arteriotomies (7 mm) and deep vessel wall trauma (5 mm) were performed, whereafter the arteriotomies were closed with running sutures. Five minutes prior to opening of the clamps (reperfusion), boluses of APC (0.8 mg/kg body weight) or vehicle alone were administered to two groups, each of 10 rabbits, in a blind random fashion. Vessel patency-rates were drastically improved by the administration of APC compared to vehicle. Correspondingly, thrombus weights were significantly lower in the APC group than in the control group. The activated partial thromboplastin time was prolonged to approximately twice the baseline throughout the 2 h observation interval in the APC group. Levels of circulating platelets were unaffected by the APC infusion, but the arteriotomy bleeding times were significantly longer in the APC group. In summary, activated protein C exerted powerful and long-acting antithrombotic effects in a microarterial model of thrombosis in rabbits.

• References

• 1 Dahlback B, Stenflo J. A natural anticoagulant pathway. Biochemistry and physiology of proteins C, S, C4b-binding protein and thrombomodulin. In: Haemostasis and Thrombosis, third edition Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Churchill Livingstone, London: 1993: 671-698
• 2 Dahlback B. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Marlar RA, Neumann A. purpura Neonatal fulminans due to homozygous protein C or proteinS deficiency. Semin Thromb Haemost 1990; 16: 299-309
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. N Engl J Med 1983; 309: 340-344
  CrossrefPubMedGoogle Scholar
• 5 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993 90. 1004-1008
  PubMedGoogle Scholar
• 6 Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1400
  CrossrefPubMedGoogle Scholar
• 7 Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
  CrossrefPubMedGoogle Scholar
• 8 Emekli NB, Ulutin ON. The protective effect of autoprothrombin Il-antico-agulant on experimental DIC formed animals. Haematologica 1980; 65: 644-651
  PubMedGoogle Scholar
• 9 Taylor FB, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925
  CrossrefPubMedGoogle Scholar
• 10 Emerick SC, Bang NU, Yan SB, Long GL, Harms CS, Huss C, Marks CA, Mattler LE, Comp PC, Esmon NB, Esmon CT. Antithrombotic properties of activated human protein C. Blood 1985; 66 (Suppl. 01) (suppl, abstr) 349a
  PubMedGoogle Scholar
• 11 Smirnov MD, Pyzh MV, Borovikov DV, Atorozhilova AN, Dobrovolski AB, Golubych VL, Gratsiansky NA. Low doses of activated protein C delay arterial thrombosis in rats. Thromb Res 1990; 57: 645-650
  CrossrefPubMedGoogle Scholar
• 12 Araki H, Nishi K, Ishihara N, Okajima K. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. Thromb Res 1991; 62: 209-216
  CrossrefPubMedGoogle Scholar
• 13 Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-642
  PubMedGoogle Scholar
• 14 Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990; 82: 578-585
  CrossrefPubMedGoogle Scholar
• 15 Wieslander J, Dougan P, Stjernquist U, Mecklenburg C. Effect of Dextran 70 and saline on thrombus formation following arteriotomy and intim-ectomy in small arteries. Microsurgery 1986; 7: 168-177
  CrossrefPubMedGoogle Scholar
• 16 Wieslander J, Dougan P. Washout of vessels with heparin does not improve patency following a severe microarterial trauma. Ann Plast Surg 1990; 24: 216-222
  CrossrefPubMedGoogle Scholar
• 17 Salemark L. Antithrombotic therapy in microvascular surgery. Experimental studies of the antithrombotic and antiplatelet effects of dextran 40, prostacyclin, and acethylsalicylic acid University of Lund, Malmo, Sweden 1991 Thesis
  PubMedGoogle Scholar
• 18 Arnljots B, Dougan P, Salemark L, Bergqvist D. Effects of streptokinase and urokinase on microvascular thrombosis and haemostasis. Scand J Plast Reconstr Hand Surg 1994; 28: 9-13
  CrossrefPubMedGoogle Scholar
• 19 Amijots B, Wieslander J, Dougan P, Salemark L. Prevention of microvascular thrombosis with low dose tissue plasminogen activator. Plast Reconstr Surg 1992; 90: 281-288
  CrossrefPubMedGoogle Scholar
• 20 Arnljots B, Dougan P, Wieslander J, Salemark L, Bergqvist D. Platelet accumulation and thrombus formation after microarterial injury: An experimental study in rabbits. Scand J Plast Reconstr Hand Surg 1994; 28: 167-175
  CrossrefPubMedGoogle Scholar
• 21 Acland RD. Microsurgery practice manual. Mosby, St Louis 1980; 58-59
  PubMedGoogle Scholar
• 22 Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization J Biol Chem 1976; 251: 355-363
  PubMedGoogle Scholar
• 23 Stenflo J, Jonsson M. Protein S, a new vitamin K-dependent protein from bovine plasma. FEBS Lett 1979; 101: 377-381
  CrossrefPubMedGoogle Scholar
• 24 Ohlin A-K, Stenflo J. Calcium-dependent interaction between the epidermal growth factor precursor-like region of human protein C and a monoclonal antibody. J Biol Chem 1987; 262: 13798-13804
  PubMedGoogle Scholar
• 25 Kisiel W. Human plasma protein C: Isolation, characterization and mechanism of activation by alpha-thrombin. J Clin Invest 1979; 64: 761-769
  CrossrefPubMedGoogle Scholar
• 26 Lehmann EL. Nonparametrics: Statistical methods based on ranks. Me Graw-Hill, New York 1975
  PubMedGoogle Scholar
• 27 Walker FJ. Regulation of bovine activated protein C by protein S: The role of the cofactor protein in species specificity. Thromb Res 1981; 22: 321-327
  CrossrefPubMedGoogle Scholar
• 28 He X, Dahlback B. Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin K-dependent protein S. Eur J Bio-chem 1993; 217: 857-865
  CrossrefPubMedGoogle Scholar
• 29 Mitchell GM, Frykman GK, Morrison WA, O’Brien B McC. The nature and effect of histopathologic injury in human avulsed arteries and veins and in experimentally-avulsed monkey arteries. Plast Reconstr Surg 1986; 78: 801-810
  CrossrefPubMedGoogle Scholar
• 30 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor V by activated protein C. J Biol Chem 1988; 263: 14884-14890
  PubMedGoogle Scholar
• 31 Arnljots B, Bergqvist D. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin - a specific thrombin inhibitor. Plast Reconstr Surg, in press
  PubMedGoogle Scholar